overview

An opportunity is curved out of adversities. COVID-19 adversity has provided us an opportunity to ramp up healthcare infrastructure not only to cater to the pressing present needs but also, to become future-ready. While Omicron is posing more critical than ever, with its ability for community spread, the need to detect the variant within the shortest possible time has grown increasingly.

In a bid to make faster clinical decisions it is important to detect the type of variant in the very beginning as many other variants including Delta is still present in the community. This will help clinicians decide whether there is a need of monoclonal antibodies for a specific case. Also, the current tests identify SARS-CoV-2. In addition, it will identify whether the sample has omicron or other variants. Genomic sequencing efforts therefore should be directed more at SARS-CoV-2 positive and Omicron negative samples, such an approach would be valuable for public health to identify newer emerging variants. As virus is continuously mutating it is important to know the devil in other variants and act appropriately failing which we may get into yet another catastrophe. Current genomic sequencing methods used to detect Omicron is expensive, hugely resource intensive and time consuming.  

FinancialExpress.com, in association with TATA MD, is organizing the virtual round table discussion - “Combatting Omicron - The way forward” to elaborate on how effective testing can help India combat the third wave of COVID-19 in an effective way. The virtual round table will be deliberated by prominent decision-makers in the healthcare domain who will be brain-storm to decode Assessing situation of disease severity, immune escape, diagnostic or therapeutic escape and evaluate the need for detection of Omicron and its sub-lineages for restricting spread.

Panelists

Dr. Nivedita Gupta

Head, Virology and Director Epidemiology, ICMR

Shri Raj Kumar Sharma

Additional Chief Secretary, Department of Health and Family Welfare, Government of Odisha

Shri Vaibhav Galriya

Principal Secretary, Department of Health and Family Welfare, Government of Rajasthan

Dr. Sudam Khade

Secretary, Ministry of Health and Family Welfare, Government of Madhya Pradesh

Dr. Arundhati Chandrashekhar

MD NHM Government of Karnataka

Dr Darez Ahamed

MD NHM, Government of Tamil Nadu

Dr. Varsha Potdar

HOD, Influenza Group NIV ICMR

Dr. Sandeep Budhiraja

Group Medical Director, Max Healthcare

Dr. Girish Krishnamurthy

CEO, Tata Medical and Diagnostics

Dr. Anuj Gupta

Senior Vice President, Product and Insights, THB

Dr V Ravi

Head - R&D Tata MD

Anurag Goel

Principal Secretary, Department of Health and Family Welfare, Government of Assam

Dr. Anurag Agarwal

Director, CSIR- Institute of Genomics and Integrated Biology

Dr. Gagandeep Kang

Indian Microbiologist and Virologist, Christian Medical College, Vellore

Key Discussion Points

Omicron- Assessing situation- disease severity, immune escape, diagnostic or therapeutic escape.

Evaluating the need for detection of Omicron and its sub-lineages for restricting spread in the shortest possible time

Importance of Early Detection and Restricting the Spread- Policy implementation and guidelines - Government Purview

Who should attend

Senior Central Government Policymakers
Senior officials from National Centre for Disease Control
Senior State Government Policymakers
Senior Officials from State Ayush department
Director of Medical Services from States
Decision-makers from Government Hospital
Dean and HOD of Medical Colleges
Key Diagnostics players in India

Contact Us

Diksha Gupta
diksha.gupta@financialexpress.com
+91 97178 54520